R & D

Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%

 This material is intended to notify the press release issued on May19 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.